key: cord-0288811-fwlb3gv6
authors: Pietzner, M.; Chua, R. L.; Wheeler, E.; Jechow, K.; Radbruch, H.; Trump, S.; Heidecker, B.; Heppner, F.; Eils, R.; Mall, M.; Sander, L. E.; Lehmann, I.; Lukassen, S.; Wareham, N. J.; Conrad, C.; Langenberg, C.
title: ELF5 is a respiratory epithelial cell-specific risk gene for severe COVID-19
date: 2022-01-19
journal: nan
DOI: 10.1101/2022.01.17.22269283
sha: 9bde64c50112705b3cd9fdb77dfaa5040c37dbd2
doc_id: 288811
cord_uid: fwlb3gv6

Despite two years of intense global research activity, host genetic factors that predispose to a poorer prognosis and severe course of COVID-19 infection remain poorly understood. Here, we identified eight candidate protein mediators of COVID-19 outcomes by establishing a shared genetic architecture at protein-coding loci using large-scale human genetic studies. The transcription factor ELF5 (ELF5) showed robust and directionally consistent associations across different outcome definitions, including a >4-fold higher risk (odds ratio: 4.85; 95%-CI: 2.65-8.89; p-value<3.1x10-7) for severe COVID-19 per 1 s.d. higher genetically predicted plasma ELF5. We show that ELF5 is specifically expressed in epithelial cells of the respiratory system, such as secretory and alveolar type 2 cells, using single-cell RNA sequencing and immunohistochemistry. These cells are also likely targets of SARS-CoV-2 by colocalisation with key host factors, including ACE2 and TMPRSS2. We also observed a 25% reduced risk of severe COVID-19 per 1 s.d. higher genetically predicted plasma G-CSF, a finding corroborated by a clinical trial of recombinant human G-CSF in COVID-19 patients with lymphopenia reporting a lower number of patients developing critical illness and death. In summary, large-scale human genetic studies together with gene expression at single-cell resolution highlight ELF5 as a novel risk gene for COVID-19 prognosis, supporting a role of epithelial cells of the respiratory system in the adverse host response to SARS-CoV-2.

The COVID-19 pandemic, caused by the coronavirus SARS-CoV-2, has overwhelmed health care 61 systems all over the world and caused more than 5.1 million deaths. The unprecedented pace of 62 vaccine development, approval, and administration 1 , has strongly reduced hospitalisations and 63 prevented hundreds of thousands of deaths 2 , and only achieving population-wide immunity will end 64 the pandemic. However, it is unclear how long immunisation from vaccines or natural infection will 65 last 3 and hospitalisation and death tolls remain high due to various factors, including the evolution of 66 novel SARS-CoV-2 variants 4-6 and the missing availability of vaccines in low-and middle-income 67 countries 7 , requiring persistent efforts to identify host factors that predispose to poor outcomes. 68

So far, older age, male sex, smoking, obesity, social deprivation, ethnicity, and a high burden of pre-69 existing conditions have been consistently identified as risk factors for a poor prognosis among COVID-70 19 patients [8] [9] [10] [11] . However, a severe disease course, including hospitalisations and fatal outcomes also 71 occur in otherwise low-risk patients. Further, the biology underlying disease progression and fatal 72 outcomes remains largely unknown, with observational studies unable to dissect cause from 73 consequence. Common variation in the human genome has now been robustly linked to a higher 74 susceptibility to severe COVID-19 outcomes 12-14 , offering novel and orthogonal insights to deep 75 molecular profiling studies in patients employing single cell sequencing or immunoprofiling 15-20 . For 76 example, common variants at 3p21.31 (possibly mapping to LZTFL1 or SLC6A20) or 12q24.13 (likely 77 OAS1) confer 30%-110% higher risk for severe outcomes of COVID-19 12-14 , with suggested roles in 78 alveolar type 2 (AT2) cells 16, 21 or modulation of the host immune response 22,23 . However, a major 79 obstacle to clinical translation of these findings is the identification of the causal genes through which 80 risk loci mediate their effect. Further, incorporating gene or protein expression quantitative trait loci 81 (QTLs) via statistical colocalisation or Mendelian randomization can highlight additional candidate 82 genes 22,24-28 . Both techniques make use of a causal chain of events. Firstly, alleles are allocated at 83 random at conception providing the opportunity to use them as instruments for causal inference. 84

Secondly, genetic variants near protein-encoding loci (cis-pQTLs) that associate with protein levels in 85 healthy individuals before viral exposure can serve as instruments for lifelong exposure to higher or 86 lower protein levels. Therefore, establishing that the same genetic signal associates with protein levels 87 and a poor prognosis of COVID-19 provides strong evidence for a causal role of the protein in the 88 aetiology of the disease. This is particularly relevant for COVID-19, which is characterized by a 89 hyperimmune response and a profound impact on the plasma proteome 29 limiting insights from ad hoc 90 cross-sectional proteomic studies. Such genetically informed strategies have already identified 91 potential druggable targets, including ACE2 24 , or modulators of the immune response such as OAS1 22 . 92 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 19, 2022. ; https://doi.org/10.1101/2022.01.17.22269283 doi: medRxiv preprint

Here, we present a proteome-wide colocalisation screen, incorporating cis-pQTLs for more than 2,300 93 protein targets across two different platforms, to identify proteomic modulators of COVID-19 94 prognosis using genome-wide summary statistics for four different outcome definitions (ranging from 95 susceptibility to severity) as released by the COVID-19 Host Genetics Initiative 30 96 (https://www.covid19hg.org/, release 6) (Fig. 1) . We demonstrate the ability of genetically informed 97 plasma proteomics to identify causal genes and proteins for severe COVID-19 and pinpoint the 98 responsible cell types through integration of orthogonal data. 99 100 101 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 19, 2022. ; https://doi.org/10.1101/2022.01.17.22269283 doi: medRxiv preprint 102 Figure 1 . Flowchart of the study design. We tested whether the same genetic signal that associated with 103 higher/lower protein abundances also associated with higher/lower risk for COVID-19 based on cis protein 104 quantitative trait loci (cis-pQTLs). We further investigated expression of targeted proteins/genes using single cell 105 and single nuclei RNA sequencing in samples of the respiratory system and confirmed expression of the most 106 robust candidate ELF5 using immunofluorescence staining.

The remaining candidate proteins showed robust evidence for selected COVID-19 outcomes in our 124 initial analysis (Fig. 2) , with G-CSF showing suggestive evidence (regional PP=64%) for a shared genetic 125 signal with greater susceptibility to infection and more severe COVID-19 prognosis, using multi-trait 126 colocalisation 31 (Supplementary Fig. 1) . 127 128 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 19, 2022. ; https://doi.org/10.1101/2022.01.17.22269283 doi: medRxiv preprint

The lead cis-pQTL for ELF5, rs766826 (MAF=35.9%), is in strong linkage disequilibrium (LD; 138 r²=0.81) with a recently identified variant rs61882275 associated with severe COVID-19 in an 139 independent study using whole genome sequencing 32 . The causal gene remained unidentified, but the 140 two closest candidate genes are ELF5 and CAT, whose encoded protein products are both captured by 141 our proteomic data. We identify ELF5 as the causal gene at this locus through a cluster of colocalising 142 phenotypes, including three different COVID-19 outcomes, ELF5 expression in the lung, and ELF5 143 abundances in plasma (PP=93%), with rs766826 being the most likely (PP=99%) underlying causal 144 variant (Fig. 3) . We further tested for colocalisation of the cis-pQTL for ELF5 and gene expression across 145 all GTEx tissues and identify colocalisation specific to expression in lung but not in other tissues, 146

including tissues with high ELF5 expression such as breast, prostate, or salivary glands (Supplementary 147 Fig. 2 ). This finding points towards a specific role of the major C-allele of rs766826 in increasing the 148 expression of ELF5 in the lung (beta=0.24, p-value=5.3x10 -15 ) with subsequent higher risk for severe 149 COVID-19 (odds ratio=1.11, p-value<5.0x10 -6 ) and higher abundances of ELF5 in blood (beta=0.06, p-150 value<5.4x10 -6 ), the latter likely via cell turnover or injury of lung tissue since ELF5 is not predicted to 151 be actively secreted into blood 33 . 152

While we identified strong evidence for a shared genetic signal (PP>80%) between the lead cis-pQTL 153 for the other candidate causal gene at this locus (CAT) and the corresponding cis-eQTL in 29 out of 49 154 tissues in GTEx v8, indicating convergence of gene and protein expression, plasma levels of catalase 155 (encoded by CAT) were unrelated to COVID-19 phenotypes. We further observed that CAT expression 156 in lung and whole blood formed a separate cluster (PP=56.6%) at the same genetic locus possibly 157 explained by rs35725681 (PP=36.8%, Supplementary Fig. 3) . 158

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 19, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 19, 2022. ; https://doi.org/10.1101/2022.01.17.22269283 doi: medRxiv preprint

While ELF5 is known to be highly expressed in multiple tissues, we demonstrate that the 168 genetic signal shared between ELF5, severe COVID-19 prognosis, and gene expression was specific to 169 the lung. We observed that rs766826 mapped to an open chromatin region in AT2 cells from the lung 170 but not in other tissues with high expression of ELF5, such as mammary gland, prostate, or kidney 171 ( Supplementary Fig. 4) , providing a potential explanation for the tissue-specific effect. 172

To systematically test phenotypic consequences of rs766826 or proxies in strong LD (r²>0.8), we 173 queried the OpenGWAS database 34 and performed colocalization for all suggestive associations 174 observed at p<10 -4 . The only association with evidence for a shared genetic signal with ELF5 expression 175 and COVID-19 prognosis was seen for lung function (PP=99%) (Supplementary Fig. 5 ) with a somewhat 176 counterintuitive effect direction seen for the ELF5-increasing and COVID-19 risk C-allele being 177 associated with better lung function (beta=0.01, p-value<1.6x10 -5 ) based on the quotient between 178 forced expired volume in 1 second (FEV1) and forced vital capacity (FVC) from spirometry in population-179 based, that is, COVID-19 free studies 35 . 180

We observed that ELF5 was almost exclusively expressed by different epithelial cells of the 182 respiratory system (Fig. 4) ELF5 expression was highest in secretory cells, AT2 but not AT1 cells showed consistent expression of 192 ELF5 in our lung data set of COVID-19-free donors 37 (Fig. 4) . This finding coincided with classical lineage 193 markers for AT2 cells such as SFTPD, which was also highly expressed in mitotic cells (Fig. 4C) . We note 194 that our proteogenomic screen prioritised SFTPD as a candidate gene for severe COVID-19 in line with 195 other studies 30,32 , leaving the possibility of potential interactions between candidate mediators. 196 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 19, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 19, 2022.

We validated the expression of ELF5 at the protein level in the different epithelial cells of the olfactory 206 mucosa and lungs using immunofluorescence staining in non-COVID-19 samples ( is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 19, 2022. To derive possible hypothesis of how ELF5 expression might be linked to severe COVID-19, we 247 collated a list of candidate genes, that were either regulated or co-expressed with ELF5 (see Methods 248 and Supplementary Table 3 ). Among the set of candidate genes were multiple members of the 249 transmembrane serine protease-family, including TMPRSS2 and TMPRSS4, which have been shown to 250 be essential for viral entry by priming of the spike protein 42,43 . We observed a positive correlation 251 between ELF5 and TMPRSS2 expression in sustentacular cells (r=0.15, p<4.5x10 -6 , Supplementary Fig.  252 10), the cell type with highest ELF5 expression in our data, but no correlation with TMPRSS4 expression. 253

The correlation with TMPRSS2 expression was also above the 95 th percentile of correlation coefficients 254 across all genes. Further, genes highly correlated with ELF5 expression were also significantly enriched 255 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 19, 2022. ; https://doi.org/10.1101/2022.01.17.22269283 doi: medRxiv preprint among collated target genes, minimizing the possibility of a measurement artefact. While such 256 correlation analysis using single-cell data must be treated with caution, overexpression of Efl5 in a 257 mouse model showed a three-fold increase in Ace2 and a two-fold higher expression of Tmprss4 in AT2 258 cells 44 , providing additional evidence that ELF5 might be involved in the regulation of key host factors 259 for SARS-CoV-2. 260

To formally test for pathways associated with ELF5 expression, we performed cell-type specific gene 261 set enrichment analysis using the collated set of putative ELF5 targets or co-expressed genes and 262 observed a consistent enrichment of biosynthetic pathways like mRNA and peptide processing and 263 possibly among genes involved in epithelial barrier formation (Supplementary Fig. 11) . The latter aligns 264 with a substantial impact of Elf5 overexpression on the differentiation of the lung epithelium in mouse 265 models of lung development, leading to dilation of the airways 44 . 266 267

We queried all identified candidate genes in the Open Targets database 45 to identify repurposing 269 opportunities for COVID-19. While none of the genes had already approved drugs or drugs in clinical 270 trials, recombinant human G-CSF (rhG-CSF), such as filgrastim and lenograstim, is used to treat 271 neutropenia caused by chemotherapy to stimulate production of granulocytes from the bone 272 marrow 46 . In line with this, phenotypic associations identified in a phenome-wide analysis of the lead 273 cis-pQTL for G-CSF showed that genetically higher plasma G-CSF was positively associated with 274 granulocyte and other white blood cell counts ( Fig. 6 and Supplementary Tab. 4) . This highlights the 275 ability of the cis-pQTL to instrument the function of the protein and allowed testing of the potential 276 effect of G-CSF supplementation for (severe) COVID-19 in silico. We observed a 25% (odds ratio: 0.75; 277 95%-CI: 0.65-0.87; p-value<1.5x10 -4 ) reduction in the risk for severe COVID-19 per 1 s.d. higher 278 genetically predicted G-CSF (Supplementary Tab. 2) . A previous smaller, independent study that used 279 a different proteomic technology observed directionally consistent results, but did not reach statistical 280 significance 47 . Together, these results provide in silico evidence that people with genetically higher 281 plasma G-CSF abundances are less likely to develop severe COVID-19 and suggests that treatment with 282 rhG-CSF might decrease the risk for symptomatic or even severe COVID-19. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 19, 2022. ; https://doi.org/10.1101/2022.01.17.22269283 doi: medRxiv preprint The identification of causal mechanisms that predispose infected individuals to a severe course 300 of COVID-19, including hospitalisation and risk of death, can guide clinical management and the 301 identification of novel drug targets or repurposing opportunities. We identified six not previously 302 reported and replicated two known causal genes and their protein targets. We demonstrate that the 303 strongest new and most robust candidate, ELF5, is specifically expressed in primary target cells of SARS-304

CoV-2 (for example, sustentacular 50 , AT2 51 , and secretory or ciliated epithelial cells 52 ) with evidence of 305 co-expression with genes encoding key host factors, such as ACE2 and TMPRSS2, using scnRNAseq data 306 across various sites of the respiratory system. We refine the association of genetic variation at ELF5 307 with severe COVID-19 to a single causal variant (rs766826) with high confidence (PP=99%) and identify 308 a tissue-specific effect of ELF5 expression in lung that is associated with a more than 4-fold higher risk 309 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 19, 2022. ; https://doi.org/10.1101/2022.01.17.22269283 doi: medRxiv preprint to develop severe COVID-19. Our results highlight high ELF5 expression in primary target cells of SARS-310 CoV-2 as a possible mechanism for severe COVID-19 with a particular focus on epithelial cells. 311

We identify a total of eight candidate proteins with robust evidence for at least one outcome, 312

with Ets-related transcription factor Elf-5 (ELF5) being the most consistent not yet reported candidate 313 associated with a more than 4-fold higher genetically predicted risk for severe COVID-19. We show 314 that ELF5 is specifically expressed in primary target cells of SARS-CoV-2 of the upper and lower 315 respiratory system, including sustentacular cells of the olfactory mucosa, secretory epithelial cells of 316 the nasopharynx, and AT2 cells in the lung using single cell/nuclei RNA sequencing and 317 immunohistochemistry. We further find genetically anchored evidence that aligns with a recent clinical 318 trial 48 suggesting human recombinant granulocyte colony-stimulating factor (G-CSF) as a potential 319 treatment option among patients with COVID-19 and severe lymphopenia to mitigate adverse 320 outcomes. 321 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 19, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 19, 2022. ; https://doi.org/10.1101/2022.01.17.22269283 doi: medRxiv preprint Although the GWAS summary statistics from the COVID-19 Host Genetics Initiative represent multiple 378 ancestries and the signal at the ELF5 locus has recently been replicated in a Brazilian cohort 72 , the pQTL 379 instruments are based on a single ancestry and genetic studies of plasma abundances of proteins in 380 other ancestries may reveal additional candidate proteins, that may help to explain the variable 381 prevalence of adverse COVID-19 outcomes across ethnicities 8 . We obtained some evidence that 382 rs766826 might act through a mechanism that is possibly unique to AT2 cells based on an open 383 chromatin region, the concrete underlying mechanism, however, remains elusive. Further studies are 384 needed to decipher the role of rs766826 in the cell-type specific expression of ELF5. The same holds 385 true for the suggested mechanisms of action for ELF5, for example co-expression with and possibly 386 regulation of ACE2 or TMPRSS2, that need to be tested in appropriate cellular and animal models, also 387 to investigate the role of ELF5 in tissues of the respiratory system more in general. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 19, 2022. ; https://doi.org/10.1101/2022.01.17.22269283 doi: medRxiv preprint

We obtained locus-specific, ±500kB of the protein encoding gene, summary statistics from our 407 genome-wide association analysis for 4,775 plasma proteins targeted by the SomaScan v4 assay and 408 1,069 targeted by the Olink proximity extension assay 28,75 . A detailed description can be found 409 elsewhere 28,75 . Briefly, plasma abundances of 4,775 protein targets were tested for protein 410 quantitative trait loci using standard GWAS workflows based on 10.4 million single nucleotide 411 polymorphisms among 10,708 individuals of white British descent. We further obtained genome-wide 412 association statistics for 1,069 proteins measured using the complementary Olink technique available 413 among a subcohort of 485 participants. We tested all protein targets with at least suggestive evidence 414 (p<10 -5 ) of a cis-pQTL or a COVID-19 signal close to the protein-encoding gene. We further treated 415 protein assays as separate instances even if those targeted the same protein between both techniques, 416

given the heterogeneity of genetic findings across both platforms 74 . We tested a total of 2,375 protein 417 targets (n=723 common to both platforms) for colocalisation with any of the four COVID-19 outcome 418 definitions. 419

We used four meta-analysed COVID-19 data sets from the June 2021 release of the COVID-19 Host 421 

To identify proteins that share a genetic architecture with any of the four different COVID-19 outcomes 427 we performed statistical colocalisation 76 in a 500kb window around the protein coding gene as 428 implemented in the R package coloc. Briefly, statistical colocalisation is a Bayesian approach that 429 provides posterior probabilities for each of five hypothesis: H0 -none of two traits has a genetic signal 430 in the region; H1 -only trait 1 has evidence for a genetic signal in the region; H2 -only trait 2 has 431 evidence for a genetic signal in the region; H3 -both traits have two distinct signals in the same 432 genomic region; and H4 -both traits share the same underlying genetic signal. We used default priors 433 and further restricted colocalisation analysis to regions with at least suggestive evidence for a cis-pQTL 434 (p<10 -5 ). To accommodate the single variant assumption of coloc, we further required each protein-435 outcome pair passing the PP threshold of 80% and that respective regional lead variants are in strong 436 LD (r²>0.8). To further acknowledge the fact that some cis-pQTLs are likely driven by measurement 437 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 19, 2022. ; https://doi.org/10.1101/2022.01.17.22269283 doi: medRxiv preprint artefacts introduced by common but benign missense variation, we performed another round of 438 colocalisation conditioning on the lead cis-pQTL in the region, if we had such evidence. 439

To derive effect directions and estimate possible effects of life-long higher/lower protein abundances 441 on COVID-19 susceptibility and severeness, we performed single-instrument Mendelian randomization 442 (MR) analysis using cis protein quantitative trait loci (cis-pQTLs) as instruments. We computed the 443 Wald ratio 77 to derive an estimate for the causal effect of a 1 s.d. increase in plasma abundances of the 444 candidate protein on the risk for COVID-19. 445

We incorporated gene expression data by testing for a shared genetic signal between protein 447 abundance in plasma and expression of the protein encoding gene in one of at least 49 tissues of the 448 GTX v8 resource 78 . We used the same colocalisation approach as described above. 449

We systematically tested for phenotypic associations for cis-pQTLs by querying the OpenGWAS 34 451 database, including proxies in high LD (r²>0.8). To test for a shared genetic signal between the 452 FEV1/FCV ratio (a proxy for lung function) and plasma levels of ELF5, we downloaded genome-wide 453 summary statistics from Shrine et al. 35 . We conditioned on two stronger independent lead signals in 454 the region (rs10836366 and rs1648123) to account for the single variant assumption in statistical 455 colocalisation. 456

We collated a list of genes with possible direction association with ELF5 by querying the Molecular 458 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 19, 2022. were purchased from OriGene (TissueFocus) and Tissue Solutions. Samples were embedded in paraffin 490 and sectioned at a 5μm thickness. Sections were deparaffinized in Roticlear (CarlRoth, A538.1) and 491 rehydrated with an ethanol series. Antigen retrieval was performed by submerging slides in 10mM 492 Sodium Citrate Buffer (Sigma-Aldrich, C999-1000ML) at 95C for 10 minutes and left to cool for 30 493 minutes. Sections were permeabilized and blocked with 5% goat serum PBST (0.5% Triton X-100 in 494 PBS) for 1 hour. Primary antibodies (1% goat serum PBST) were then added onto the tissues and left 495 to incubate overnight. This was followed by secondary antibody (1% goat serum PBST) labelling for 1 496 hour at room temperature. Antibodies used in this study can be found in Supplementary Table 6 . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 19, 2022. ; https://doi.org/10.1101/2022.01.17.22269283 doi: medRxiv preprint (ThermoFischer, H3569) for 5 minutes, washed with 1X PBS, and mounted with VECTASHIELD® 502

HardSet™ Antifade Mounting Medium (Vector Laboratories, H-1400-10). Stained slides were visualized 503 with a Leica SP8 confocal microscope. Images were processed and assembled with FIJI 89 . 504 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 19, 2022. ; https://doi.org/10.1101/2022.01.17.22269283 doi: medRxiv preprint

The story behind COVID-19 vaccines

Infections, hospitalisations, and deaths averted via a nationwide vaccination 507 campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a 508 retrospective surveillance study

Immunological memory to SARS-CoV-2 assessed for up to 8 months after 510 infection

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in 514 England

Untangling introductions and persistence in COVID-19 resurgence in Europe

Vaccine nationalism and the dynamics and control of SARS-CoV-2

Factors associated with COVID-19-related death using OpenSAFELY. 520

Risk Factors Associated with Mortality among Patients with COVID-19 in 522 Intensive Care Units in Lombardy, Italy

Demographic risk factors for COVID-19 infection, severity, ICU admission and 524 death: a meta-analysis of 59 studies

Risk factors for severe and critically ill COVID-19 patients: A review

Genetic mechanisms of critical illness in COVID-19

14. Initiative, C.-19 H. G. Mapping the human genetic architecture of COVID-19

COVID-19 severity correlates with airway epithelium-immune cell 534 interactions identified by single-cell analysis

COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets. 536

A molecular single-cell lung atlas of lethal COVID-19

Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, 540 and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes

Hypertension delays viral clearance and exacerbates airway 545 hyperinflammation in patients with COVID-19

Identification of LZTFL1 as a candidate effector gene at a COVID-19 risk 547 locus

A Neanderthal OAS1 isoform protects individuals of European ancestry against 549 COVID-19 susceptibility and severity

A prenylated dsRNA sensor protects against severe COVID-19

Actionable druggable genome-wide Mendelian randomization identifies 553 repurposing opportunities for COVID-19

A proteome-wide genetic investigation identifies several SARS-CoV-2-555 exploited host targets of clinical relevance

Integrative genomic analyses identify susceptibility genes underlying 557 COVID-19 hospitalization

Mendelian randomisation identifies alternative splicing of the FAS death 559 receptor as a mediator of severe COVID-19

Mapping the proteo-genomic convergence of human diseases

Longitudinal proteomic analysis of severe COVID-19 reveals survival-564 associated signatures, tissue-specific cell death, and cell-cell interactions

Mapping the human genetic architecture of COVID-19: an 567 update

A fast and efficient colocalization algorithm for identifying shared genetic 569 risk factors across multiple traits

Whole genome sequencing identifies multiple loci for critical illness 571 caused by COVID-19

The MRC IEU OpenGWAS data infrastructure

New genetic signals for lung function highlight pathways and chronic 577 obstructive pulmonary disease associations across multiple ancestries

Pulmonary post-mortem findings in a series of COVID-19 cases from northern 580 Italy: a two-centre descriptive study

SARS -CoV-2 receptor ACE 2 and TMPRSS 2 are primarily expressed in 582 bronchial transient secretory cells

Type 2 alveolar cells are stem cells in adult lung

Alveolar progenitor and stem cells in lung 586 development, renewal and cancer

Dedifferentiation of committed epithelial cells into stem cells in vivo

Multiple stromal populations contribute to pulmonary fibrosis without 590 evidence for epithelial to mesenchymal transition

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a 593 Clinically Proven Protease Inhibitor

TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal 595 enterocytes

Misexpression of ELF5 disrupts lung 597 branching and inhibits epithelial differentiation

Open Targets Platform: supporting systematic drug-target identification and 599 prioritisation

Contribution of glycosylated recombinant human granulocyte colony-601 stimulating factor (lenograstim) use in current cancer treatment: review of clinical data. 602 Expert Opin

Circulating Cytokines and Coronavirus Disease: 604 A Bi-Directional Mendelian Randomization Study

Effect of Recombinant Human Granulocyte Colony-Stimulating Factor for 606 Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A Randomized Clinical 607 Trial

The Allelic Landscape of Human Blood Cell Trait Variation and Links to 609

Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system 611 suggests mechanisms underlying COVID-19-associated anosmia

Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and 614 demographics

SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the 616 Respiratory Tract

ELF5 isoform expression is tissue-specific and significantly altered in cancer. 618 Breast Cancer Res

Elf5 Is an Epithelium-Specific, Fibroblast Growth 620 Factor-Sensitive Transcription Factor in the Embryonic Lung

Coordinate regulation of ELF5 and EHF at the chr11p13 CF modifier region

A new Elf5CreERT2-GFP BAC transgenic mouse model for tracing Elf5 cell 625 lineages in adult tissues

The role of Scgb1a1+ Clara cells in the long-term maintenance and repair 627 of lung airway, but not alveolar, epithelium

Real-time tracking of self-reported symptoms to predict potential COVID-19

Signs and symptoms to determine if a patient presenting in primary care or 631 hospital outpatient settings has COVID-19

Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous 633 system entry in individuals with COVID-19

Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the 635 respiratory and olfactory mucosae but spares the olfactory bulb

SARS-CoV-2 Receptors and Entry Genes Are Expressed in the Human 638

Massive transient damage of the olfactory epithelium associated with 640 infection of sustentacular cells by SARS-CoV-2 in golden Syrian hamsters

SARS-CoV-2 infection in the mouse olfactory system

The UGT2A1 / UGT2A2 locus is 644 associated with COVID-19-related anosmia

Pre-activated antiviral innate immunity in the upper airways controls early 646 SARS-CoV-2 infection in children

GM-CSF-based treatments 648 in COVID-19: reconciling opposing therapeutic approaches

Distinct inflammatory profiles distinguish COVID-19 from influenza with 651 limited contributions from cytokine storm

A neutrophil activation signature predicts critical illness and mortality in 653 COVID-19

The Effect of Neutropenia and Filgrastim (G-CSF) on Cancer Patients With 655

COVID-19) Infection

A Multicenter Analysis of the Outcome of Cancer Patients with Neutropenia 657 and COVID-19 Optionally Treated with Granulocyte-Colony Stimulating Factor (G-CSF): A 658 Comparative Analysis

Genetic risk factors and Covid-19 severity in Brazil: results from BRACOVID 660 Study

Large-Scale Multi-omic Analysis of COVID-19 Severity

Cross-platform proteomics to advance genetic prioritisation strategies

Synergistic insights into human health from aptamer-and antibody-based 666 proteomic profiling

Bayesian test for colocalisation between pairs of genetic association 668 studies using summary statistics

Mendelian 670 randomization: using genes as instruments for making causal inferences in epidemiology

The GTEx Consortium atlas of genetic regulatory effects across human 673 tissues

Gene set enrichment analysis: a knowledge-based approach for 675 interpreting genome-wide expression profiles

Enrichr: a comprehensive gene set enrichment analysis web server 2016 678 update

The harmonizome: a collection of processed datasets gathered to serve 680 and mine knowledge about genes and proteins

ELF5 suppresses estrogen sensitivity and underpins the acquisition of 682 antiestrogen resistance in luminal breast cancer

Improving the diagnostic yield of exome-sequencing by predicting gene-684 phenotype associations using large-scale gene expression analysis

SARS-CoV-2-mediated dysregulation of metabolism and autophagy 687 uncovers host-targeting antivirals

Single-cell analysis of olfactory neurogenesis and differentiation in adult 689 humans

SoupX removes ambient RNA contamination from droplet-based 691 single-cell RNA sequencing data

Integrating single-cell 693 transcriptomic data across different conditions, technologies, and species

Fiji: an open-source platform for biological-image analysis

We are grateful to all Fenland volunteers and to the General Practitioners and practice staff for 702 assistance with recruitment. We thank the Fenland Study Investigators, Fenland Study Co-ordination 703 team and the Epidemiology Field, Data and Laboratory teams

We further acknowledge support for genomics from the Medical Research Council 709 (MC_PC_13046). CL, EW, MP, and NJW are funded by the Medical Research Council (MC_UU_00006/1 710 -Aetiology and Mechanisms)

BrainBank/BioBank of the Department of Neuropathology at the Charité -Universitätsmedizin Berlin, 712 funded by the Deutsche Forschungsgemeinschaft

Germany´s Excellence Strategy -EXC-2049 -390688087. COVID-19 autopsies were supported by the 714 the German Network University Medicine NUM FKZ 01KX2021 Organostrat and Defeat Pandemics

AUTHOR CONTRIBUTIONS

Conceptualization: CL, MP, CC 718 Data curation/Software: MP, RLC, SL, EW 719 Formal Analysis: MP, RLC, SL, EW 720 Methodology: SL, ST 721 Visualization: MP, RLC, SL, KJ 722 Experiments: RLC, KJ, HR 723 Funding acquisition: CL, NJW, CC, IL

Summary statistics for protein levels are available from www.omicscience.org. Summary statistics for 732

data sets are available 733 under the accession IDs: olfactory mucosa (GSE139522), nasopharynx (EGAS00001005461), and lungs 734 (EGAS00001004689, EGAS00001004419, SAMEA6848756, SAMEA6848761

Associated code and scripts for the analysis will be made available on GitHub upon 736 publication